- Conditions
- Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source, Recurrent Ischemic Stroke
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Stroke, Secondary Prevention
- Interventions
- optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 5,390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 110
- States / cities
- Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more
- Conditions
- Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Right-To-Left Atrial Shunt, Patent Foramen Ovale
- Interventions
- NeuralBot Investigational System, Transthoracic Echocardiography (TTE)
- Diagnostic Test
- Lead sponsor
- NovaSignal Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Portland, Oregon • Chattanooga, Tennessee + 3 more
- Conditions
- Embolic Stroke of Undetermined Source
- Interventions
- Not listed
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Stanford, California • Joliet, Illinois • Greensboro, North Carolina + 4 more
- Conditions
- Stroke
- Interventions
- Rivaroxaban (Xarelto, BAY59-7939), Acetylsalicylic acid (Aspirin, BAY1019036), Rivaroxaban-Placebo, Aspirin-Placebo
- Drug · Other
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 7,213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Long Beach, California • Stanford, California + 32 more